$Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors$

Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors

CEP-2563 dihydrochloride (CEP-2563) is a soluble lysinyl-beta-alanyl ester of CEP-751, a potent inhibitor of the trk family of receptor tyrosine kinases and the platelet-derived growth factor (PDGF) receptor tyrosine kinase. CEP-2563 was developed because of the limited aqueous solubility of CEP-751...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2004-11, Vol.22 (4), p.449-458
Hauptverfasser:	Undevia, Samir D, Vogelzang, Nicholas J, Mauer, Ann M, Janisch, Linda, Mani, Sridhar, Ratain, Mark J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Androgens Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - toxicity Binding sites Cancer therapies Carbazoles - pharmacokinetics Carbazoles - therapeutic use Catheters Clinical trials Cohort Studies Creatinine Dipeptides - pharmacokinetics Dipeptides - therapeutic use Dose-Response Relationship, Drug Drug dosages Drug Hypersensitivity - etiology Electrocardiography Female Growth factors Humans Hypotension - chemically induced Kinases Laboratories Male Maximum Tolerated Dose Melanoma Middle Aged Neoplasms - drug therapy Ovarian cancer Patients Pharmacokinetics Phosphatase Prodrugs - pharmacokinetics Prodrugs - toxicity Prostate cancer Receptor Protein-Tyrosine Kinases - antagonists & inhibitors Time Factors Toxicity Toxicology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!